Literature DB >> 31344496

Proteomics of Naja kaouthia venom from North East India and assessment of Indian polyvalent antivenom by third generation antivenomics.

Archana Deka1, Aditi Gogoi1, Diganta Das2, Jayaditya Purkayastha3, Robin Doley4.   

Abstract

In the present study, venom composition, toxic effects, and immunological characteristics of Naja kaouthia venom from North East India has been studied. Using RP-HPLC, venom components were separated and proteins in the fractions were identified using ESI-LC MS/MS. Proteins identified belong to 9 different snake venom protein families. Three finger toxins and PLA2 were the most abundant protein families detected by mass spectrometry analysis. The other minor proteins families identified in the venom were kunitz-type serine inhibitors, waprin, L-amino acid oxidase, CRISP, vespyrn, nerve growth factor and metalloproteinase. This proteome composition correlated with the tested enzymatic and toxic activities of the venom. Western blot and third generation antivenomics analysis using Vins polyvalent antivenom revealed immunoreactivity towards Naja kaouthia venom of North East India. Concentration-dependent immunocapturing profile carried out using RP-HPLC displayed immunerecognition of majority of venom proteins of Naja kaouthia except few three-finger toxins. Presence of such non-immunodepleted toxins apparently may affect the performance of Vins polyvalent antivenom. Thus, inclusion of antibodies of most relevant non-immunorecognized toxins in antivenom might help to improve the quality of antivenom. BIOLOGICAL SIGNIFICANCE: Envenomings by genus Naja, represent a serious medical problem in Asian countries including North east India. In North East India, Naja kaouthia is most prevalent cobra species causing a large number of fatalities. To gain deeper insight into the spectrum of medically relevant toxins, we applied proteomics approach to unveil the proteome profile of Naja kaouthia venom. The proteomic analysis divulged the presence of two major protein families: three finger toxins and phospholipases A2. In general, polyvalent antivenom is administered for Naja kaouthia envenomings, however, this venom is not included in the immunization mixtures (only Indian Big Four venoms) for production of these polyvalent antivenoms. For the first time, third generation antivenomics approach was used to decipher maximal binding capacity of Indian polyvalent antivenom against Naja kaouthia venom. Although Vins polyvalent antivenom was effective in immunocapturing majority of venom components, however, large amount of antivenom was required to immunocapture the venom proteins. Moreover, the study revealed poor immunorecognition capacity of Vins antivenom towards four three finger toxin subtypes. This may have significant impact on antivenom efficacy in treating Naja kaouthia envenomings.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antivenom; Antivenomics; Naja kaouthia; Snake venom; Third-generation antivenomics; Venomics

Year:  2019        PMID: 31344496     DOI: 10.1016/j.jprot.2019.103463

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  9 in total

1.  Synthetic antibodies block receptor binding and current-inhibiting effects of α-cobratoxin from Naja kaouthia.

Authors:  Shane Miersch; Guillermo de la Rosa; Rasmus Friis; Line Ledsgaard; Kim Boddum; Andreas H Laustsen; Sachdev S Sidhu
Journal:  Protein Sci       Date:  2022-05       Impact factor: 6.725

2.  The Effect of Naja naja oxiana Snake Venom Against Leishmania tropica Confirmed by Advanced Assays.

Authors:  Iraj Sharifi; Fatemeh Tabatabaie; Saeideh Nikpour; Mahshid Mostafavi; Razieh Tavakoli Oliaee; Fatemeh Sharifi; Zahra Babaei; Elham Jafari; Ehsan Salarkia; Delavar Shahbazzadeh
Journal:  Acta Parasitol       Date:  2020-11-06       Impact factor: 1.440

3.  The risk of exotic venomous snakes to public health in Brazil.

Authors:  Paulo Sérgio Bernarde; Fan Hui Wen; Wuelton Marcelo Monteiro
Journal:  Rev Soc Bras Med Trop       Date:  2021-03-22       Impact factor: 1.581

4.  Development of a Broad-Spectrum Antiserum against Cobra Venoms Using Recombinant Three-Finger Toxins.

Authors:  Bing-Sin Liu; Bo-Rong Jiang; Kai-Chieh Hu; Chien-Hsin Liu; Wen-Chin Hsieh; Min-Han Lin; Wang-Chou Sung
Journal:  Toxins (Basel)       Date:  2021-08-10       Impact factor: 4.546

5.  In Vitro neurotoxicity and myotoxicity of Malaysian Naja sumatrana and Naja kaouthia venoms: Neutralization by monovalent and Neuro Polyvalent Antivenoms from Thailand.

Authors:  Nor Asyikin Zukifli; Zalikha Ibrahim; Iekhsan Othman; Ahmad Khaldun Ismail; Janeyuth Chaisakul; Wayne C Hodgson; Muhamad Rusdi Ahmad Rusmili
Journal:  PLoS One       Date:  2022-09-12       Impact factor: 3.752

6.  Venom-gland transcriptomic, venomic, and antivenomic profiles of the spine-bellied sea snake (Hydrophis curtus) from the South China Sea.

Authors:  Hong-Yan Zhao; Lin Wen; Yu-Feng Miao; Yu Du; Yan Sun; Yin Yin; Chi-Xian Lin; Long-Hui Lin; Xiang Ji; Jian-Fang Gao
Journal:  BMC Genomics       Date:  2021-07-08       Impact factor: 3.969

7.  Extending Metabolomic Studies of Apis mellifera Venom: LC-MS-Based Targeted Analysis of Organic Acids.

Authors:  Magdalena Pawlak; Agnieszka Klupczynska; Zenon J Kokot; Jan Matysiak
Journal:  Toxins (Basel)       Date:  2019-12-28       Impact factor: 4.546

8.  Proteomic Investigations of Two Pakistani Naja Snake Venoms Species Unravel the Venom Complexity, Posttranslational Modifications, and Presence of Extracellular Vesicles.

Authors:  Aisha Manuwar; Benjamin Dreyer; Andreas Böhmert; Anwar Ullah; Zia Mughal; Ahmed Akrem; Syed Abid Ali; Hartmut Schlüter; Christian Betzel
Journal:  Toxins (Basel)       Date:  2020-10-22       Impact factor: 4.546

9.  Assessment of quality and pre-clinical efficacy of a newly developed polyvalent antivenom against the medically important snakes of Sri Lanka.

Authors:  Aparup Patra; Bhargab Kalita; Milind V Khadilkar; Nitin C Salvi; Pravin V Shelke; Ashis K Mukherjee
Journal:  Sci Rep       Date:  2021-09-14       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.